<DOC>
	<DOCNO>NCT00501644</DOCNO>
	<brief_summary>Primary Objectives : 1 . Determine response rate , time progression , toxicity schedule carboplatin IV ( intravenous ) infusion , GM-CSF rIFN-g SC ( subcutaneous injection ) patient potentially platinum-sensitive recurrent Müllerian carcinoma . 2 . Determine whether treatment schedule associate : 1. increase level monocyte ( &gt; 2-fold absolute number 1000 cells/ml , ) LN-DR+ DC ( CD11c+ CD123+ subset ) 2. induction prim activation MO/MA ( monocytes/ macrophage ) , maturation DC ( dendritic cell ) . 3 . Determine toxicity profile consolidation treatment IP ( intraperitoneal ) injection rIFN-g add carboplatin ( IV ) GM-CSF ( SC ) 4 doses/course . 4 . Determine effect carboplatin plus GM-CSF rIFN-g quality life patient platinum-sensitive Müllerian carcinoma . 5 . To begin exploration cell surface proteins purify activated peripheral blood ascites monocyte/macrophages treatment GM-CSFand rIFN-g .</brief_summary>
	<brief_title>Chemoimmunotherapy Study Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description>Carboplatin chemotherapy drug use treatment ovarian cancer . GM-CSF protein use increase production white blood cell . rIFN-g protein stimulate cell immune system . Participants need pre-study blood work ( 4 teaspoon ) part evaluation study entry . In addition , chest x-ray CT scan abdomen pelvis need do treatment . Participants study receive frequently use dose carboplatin vein 1 hour every 28 day . In addition , GM-CSF give 7 day rIFN-g give 2 day chemotherapy . Both drug give injection skin . They repeat chemotherapy course participant receive . GM-CSF rIFN-g use try stimulate immune system belief add effectiveness chemotherapy tumor . During course chemotherapy treatment , blood sample take order evaluate blood count response GM-CSF . Participants need remain Houston area begin first injection GM-CSF 9 day follow carboplatin infusion first course . QOL form complete 5 separate time point first course chemotherapy . Later course 2 time point completion QOL form . The completion form help researcher evaluate effect carboplatin 2 protein participant quality life . Participants receive 3 course treatment ( course include 1 treatment carboplatin follow 2 separate treatment cycle GM-CSF rIFN-g ) evaluate tumor response . If tumor responding , 3 additional course give . If 6 course treatment , tumor completely respond evidence disease , 4 additional course give completion therapy . If tumor still respond 6 course completely go away , additional course give long tumor respond completion therapy consider . Completion therapy include carboplatin give every 28 day vein along injection GM-CSF skin chemotherapy . Injections rIFN-g give directly abdomen abdominal catheter possible . If possible , rIFN-g give injection skin . Participants may choose receive rIFN-g catheter completion phase continue receive skin chemotherapy . A maximum 4 additional course give phase study . Participants whose disease get bad take study . Participants intolerable side effect study drug also take study treatment . Participants follow CT scan every 3 course treatment . Following completion treatment , participant need return M. D. Anderson every 3 month follow-up exam . This include physical exam , blood work , CT scan . This investigational study . A total 65 patient take part study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>1 . Patients Müllerian carcinoma ( primary epithelial ovarian , primary peritoneal , fallopian tube ) response platinumbased chemotherapy chemotherapy treatmentfree interval least 6 month . These patient designate potentially platinumsensitive . 2 . Measurable disease radiological clinical examination parameter . 3 . No prior immunotherapy . 4 . No concurrent steroid radiation therapy . 5 . Adequate hematological parameter ( ANC &gt; /= 1500 cells/UL , platelet &gt; /= 100,000 cells/UL 6 . Adequate renal function ( serum creatinine &lt; /= 1.5 mg/dl ) 7 . Adequate hepatic function ( serum bilirubin &lt; /= 1.5 mg/dl ) 8 . SGOT SGPT &lt; /= 2.5 normal 9 . Zubrod status &lt; /= 2 10 . Signed informed consent 11 . Patients 2 prior therapy regimen ( 1st line platinum platinum reinduction count one ) 1 . Pregnant lactate woman 2 . Patients brain metastases 3 . Serum albumin &lt; 3 gm/dl 4 . Weight loss &gt; 10 % 4 month 5 . Radiation therapy whole abdomen 6 . History clinical EKG finding suggestive active ( within last 6 month ) heart disease 7 . Patients active autoimmune inflammatory bowel disease 8 . Patients active serious infection serious underlie medical condition would otherwise impair ability receive protocol treatment . 9 . Dementia significantly alter mental status would prohibit understanding and/or give informed consent . 10 . Patients prior hypersensitivity platinum agent 11 . Patients history malignancy , exception nonmelanomatous skin cancer ; unless complete remission therapy minimum 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Müllerian Carcinomas</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Epithelial Ovarian</keyword>
	<keyword>Peritoneal</keyword>
	<keyword>Fallopian Tube</keyword>
	<keyword>Chemoimmunotherapy</keyword>
	<keyword>Platinum Sensitive Müllerian</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Interferon Gamma</keyword>
	<keyword>Quality Life</keyword>
	<keyword>QOL</keyword>
</DOC>